Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Lineage Cell Therapeutics (LCTX) Asset Writedowns and Impairment (2016 - 2025)

Lineage Cell Therapeutics' Asset Writedowns and Impairment history spans 7 years, with the latest figure at $14.8 million for Q2 2025.

For Q2 2025, Asset Writedowns and Impairment changed N/A year-over-year to $14.8 million; the TTM value through Dec 2025 reached $14.8 million, up 9900.0%, while the annual FY2025 figure was $14.8 million, N/A changed from the prior year.
Asset Writedowns and Impairment reached $14.8 million in Q2 2025 per LCTX's latest filing, up from $148000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of $14.8 million in Q2 2025 to a low of $14.8 million in Q2 2025.